Draftkings Inc. diskutieren
DraftKings Inc. (NASDAQ: DKNG) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $50.00 price target on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its price target raised by analysts at Susquehanna from $54.00 to $56.00. They now have a "positive" rating on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $58.00 price target on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its price target raised by analysts at Benchmark Co. from $50.00 to $52.00. They now have a "buy" rating on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its price target raised by analysts at BTIG Research from $53.00 to $55.00. They now have a "buy" rating on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its price target raised by analysts at BMO Capital Markets from $51.00 to $54.00. They now have an "outperform" rating on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its price target raised by analysts at Barclays PLC from $52.00 to $54.00. They now have an "overweight" rating on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its price target raised by analysts at Jefferies Financial Group Inc. from $52.00 to $54.00. They now have a "buy" rating on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its price target raised by analysts at Stifel Nicolaus from $50.00 to $51.00. They now have a "buy" rating on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its price target raised by analysts at UBS Group AG from $56.00 to $60.00. They now have a "buy" rating on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $60.00 price target on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its price target lowered by analysts at Stifel Nicolaus from $51.00 to $50.00. They now have a "buy" rating on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its price target lowered by analysts at Susquehanna from $56.00 to $49.00. They now have a "positive" rating on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its price target lowered by analysts at Wells Fargo & Company from $54.00 to $53.00. They now have an "overweight" rating on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its price target lowered by analysts at Guggenheim from $53.00 to $52.00. They now have a "buy" rating on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $60.00 to $58.00. They now have an "outperform" rating on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $50.00 price target on the stock.
Ratings data for DKNG provided by MarketBeat
DraftKings Inc. (NASDAQ: DKNG) had its price target lowered by analysts at Barclays PLC from $54.00 to $53.00. They now have an "overweight" rating on the stock.
Ratings data for DKNG provided by MarketBeat
Neueste Beiträge
StockNews_com in Ampio Pharmaceuticals Inc. diskutieren